



Product Portfolio

# Nature-backed probiotic solutions

Tailor-made probiotic blends, for specific therapeutic and health needs



# Why AB-BIOTICS?

We offer a diversified product range to meet the needs of our partners

Research and development of a vast generation of natural probiotic strains formulated not only to meet therapeutic needs but also to maintain human health.

## Clinically-proven probiotic solutions

1. Development of probiotic blends with relevant medical applications for every stage of life.
2. Complete *in vitro* and *in vivo* investigation process.
3. Clinical validation in humans. Gold standard randomised, double-blind, placebo-controlled clinical trials.



## Unique strains with characterized mechanism of action

1. Collection of hundreds of bacteria strains, creating a private strain bank. Microbiota samples taken from non-industrialised societies (human resident bacteria).
2. Characterisation of the strains' mechanism of action, after selecting those with outstanding phenotypes
3. **Patent protection.**



## Ready-to-market products

1. Generation of the final product concept (dose, delivery form, formulation and posology), following all quality and regulatory processes.
2. Development of a value proposition and positioning of the final product, taking into consideration specific market needs and competitors.
3. Proven safety and efficacy.

# Therapeutic areas and finished products

i3.1™ AB-DIGEST™

AB-KOLICARE™ AB-DIGEST™ kids AB-DENTALAC™ AB-IMPLALAC™

LipiGO® AB-LIFE™

AB-DR7™ AB-IMMUNO™

AB-MIND™

AB-CYSCARE™ INNERIM™

AB-SAKEI 65®

AB-PROTEARS®





## Our probiotic strains



<i>Pediococcus acidilactici</i> KABP™ 021	CECT 7483	<ul style="list-style-type: none"> <li>→ <b>Antagonistic activity</b> against IBS-related bacteria</li> <li>→ Synthesis of SCFA (<b>acetate</b>)</li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 022	CECT 7484	<ul style="list-style-type: none"> <li>→ Enhancement of the <b>intestinal barrier</b> via synthesis of poly-P granules</li> <li>→ Reduction of inflammation through the production of <b>acetylcholine</b></li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 023	CECT 7485	<ul style="list-style-type: none"> <li>→ <b>Antagonistic activity</b> against IBS-related pathogenic bacteria</li> <li>→ Synthesis of SCFA (<b>acetate</b>)</li> </ul>
<i>Lacticaseibacillus rhamnosus</i> GG	ATCC 531033	<ul style="list-style-type: none"> <li>→ Strong adhesive capacity to the intestinal epithelium</li> <li>→ Modulation of the innate and adaptative immune responses</li> <li>→ Synthesis of <b>p40 and p75 proteins</b>, that protect the epithelial barrier, enhance intestinal cells' function and promote the production of IgA</li> <li>→ Antagonistic activity against gastrointestinal tract pathogens</li> </ul>
<i>Bifidobacterium longum</i> KABP™ 042	CECT 7894	<ul style="list-style-type: none"> <li>→ Antagonistic activity against colic-related pathogenic bacteria</li> <li>→ Digestion of HMOs, supporting a <b>healthy gut colonisation</b></li> <li>→ Homofermentative metabolism (no CO<sub>2</sub> production)</li> </ul>
<i>Pediococcus pentosaceus</i> KABP™ 041	CECT 8330	<ul style="list-style-type: none"> <li>→ Induction of anti-inflammatory molecules (<b>IL-10</b>)</li> <li>→ Homofermentative metabolism (no CO<sub>2</sub> production)</li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 051	CECT 7481	<ul style="list-style-type: none"> <li>→ <b>Good aggregation and adhesion</b> to tissues in the oral cavity, preventing overgrowth of undesirable bacteria</li> <li>→ Good tolerance against lysozyme and most antiseptics found in mouthwashes</li> <li>→ <b>Antagonistic activity</b> against oral pathogenic bacteria</li> <li>→ Low production of acid and malodorous compounds</li> </ul>
<i>Levilactobacillus brevis</i> KABP™ 052	CECT 7480	
<i>Pediococcus acidilactici</i> KABP™ 053	CECT 8633	

IBS: Irritable Bowel Syndrome. SCFA: short chain fatty acids. poly-P granules: polyphosphate granules. IgA: immunoglobulin A. HMOs: human milk oligosaccharides. IL-10: interleukin 10



## Our probiotic strains




<i>Lactiplantibacillus plantarum</i> KABP™ 011	CECT 7527	<ul style="list-style-type: none"> <li>→ Modification of the enterohepatic cycle through a high <b>BSH activity</b></li> <li>→ Capacity to capture intestinal cholesterol, promoting its excretion</li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 012	CECT 7528	
<i>Lactiplantibacillus plantarum</i> KABP™ 013	CECT 7529	
<i>Saccharomyces cerevisiae</i> postbiotic	BGCC extract	<ul style="list-style-type: none"> <li>→ Specific <b>binding to saturated fats</b>, limiting its absorption through the intestinal wall</li> <li>→ Beneficial effects on the <b>metabolism of glucose</b>, reducing blood insulin levels after a meal</li> </ul>
<i>Lactobacillus plantarum</i> DR7®	KCTC 13909BP	<ul style="list-style-type: none"> <li>→ Regulation of neuroactive molecules, with effects on the <b>serotonin-kynurenine</b> pathway and <b>dopamine-norepinephrine</b> pathway</li> <li>→ Modification of gut bacteria concentrations affecting the <b>gut-brain axis</b></li> <li>→ Improvement of anti-inflammatory (IL-10) versus pro-inflammatory (TNF-<math>\alpha</math>, IFN-<math>\gamma</math>) signals</li> <li>→ Reduction of stress-associated molecules (<b>cortisol</b>) plasma levels.</li> <li>→ Antioxidative properties</li> <li>→ <b>Direct antagonistic activity</b> against pathogens linked with URTIs</li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 031	CECT 7315	<ul style="list-style-type: none"> <li>→ Synthesis of acetate linked with an increase in IgA (<b>increased immune protection</b>) and induction of T-cells</li> <li>→ Modulation of several anti and proinflammatory cytokines</li> <li>→ Reduction of TGF-<math>\beta</math>1, <b>diminishing immunosuppression</b></li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 032	CECT 7316	

BSH: bile salt hydrolase. SCFA: short chain fatty acids. BGCC:  $\beta$ -glucan and chitin chitosan. IL-10: interleukin 10. TNF- $\alpha$ : tumor necrosis factor alpha. IFN- $\gamma$ : interferon gamma. URTIs: upper respiratory tract infections. GABA: gamma-aminobutyric acid. IgA: immunoglobulin A. TGF- $\beta$ 1: transforming growth factor beta 1



## Our probiotic strains



<i>Latilactobacillus sakei</i> proBio 65	KCTC 10755BP	<ul style="list-style-type: none"><li>→ Stimulation of <b>regulatory lymphocytes</b>, linked with an increased production of several cytokines (IL-10, IL-12, IL-17, IFN-<math>\gamma</math>)</li><li>→ Reduction of chemokines associated with allergic responses and inflammatory processes</li></ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 062	CECT 8675	<ul style="list-style-type: none"><li>→ <b>Antagonistic activity</b> against uropathogenic bacteria</li><li>→ Survival of the vaginal environment</li></ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 063	CECT 8677	<ul style="list-style-type: none"><li>→ <b>Biofilm formation and acidification capacity</b>, preventing overgrowth of undesirable bacteria</li></ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 061	CECT 7504	<ul style="list-style-type: none"><li>→ <b>Antagonistic activity</b> against pathogenic bacteria linked with infections such as bacterial vaginosis</li><li>→ High adhesion capacity to the vaginal epithelium</li><li>→ <b>Acidification capacity</b> preventing overgrowth of undesirable bacteria</li><li>→ Antagonistic activity against <i>Candida</i> spp. High resistance to simulated candidiasis vaginal environment</li></ul>

IL-10: interleukin 10. IL-12: interleukin 12. TNF- $\alpha$ : tumor necrosis factor alpha. IL-17: interleukin 17. IFN- $\gamma$ : interferon gamma. LPS: lipopolysaccharide. FoxO1: forkhead box protein O1

# Our probiotic blends - Gastrointestinal health



CAPSULES

STICKS

DROPS

## i3.1™

*P. acidilactici* KABP™ 021  
*L. plantarum* KABP™ 022  
*L. plantarum* KABP™ 023

### Indication

- Irritable bowel syndrome (IBS)
- Lactose intolerance
- Digestive wellbeing

Daily dose in final product: 3 billion CFU

### Scientific support

1. Lorenzo-Zúñiga V, et al. i3.1, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. *World J. Gastroenterol.* 20, 8709–8716 (2014).
2. Barraza-Ortiz DA, et al. Combination of a probiotic and an antispasmodic increases quality of life and reduces symptoms in patients with irritable bowel syndrome: a pilot study. *Dig. Dis.* (2020)
3. Cano-Contreras A, et al. Efficacy of probiotic i3.1 symptomatic improvement in patients with lactose intolerance. *J Clin. Gastroenterol.* (2020).
4. Lorén V, et al. Comparative effect of the i3.1 probiotic formula in two animal models of colitis. *Probiotics Antimicrob. Proteins.* 9, 71–80 (2017).
5. Perez M, et al. Derived postbiotics of a multi-strain probiotic formula clinically validated for the treatment of Irritable bowel syndrome. *FASEB J.* 34, 1–1 (2020).

Additional compounds: Vitamin D



SHOTS

STICKS

## AB-DIGEST™

*B. longum* KABP™ 042  
*P. pentosaceus* KABP™ 041  
*L. rhamnosus* GG

### Indication

- Diarrhea, antibiotic co-treatment
- Microbiota restoration
- Immune support

Daily dose in final product: 6 billion CFU

### Scientific support\*

1. Hempel S, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA.* 9, 1959–69 (2012).
2. Szajewska H, et al. Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG in the prevention of antibiotic-associated diarrhoea in children and adults. *Aliment. Pharmacol. Ther.* 42, 1149–57 (2014).
3. Tintore M, et al. Probiotic treatment with AB-KOLICARE causes changes in the microbiota which correlate with a reduction in crying time. *Int. J. Pharma Bio Sci.* 8, 281–288 (2017).
4. Astó E, et al. Equivalence of a novel *Lactobacillus rhamnosus* isolate to the reference ATCC53103 strain. Poster presented at SEPyP congress (2018).

Additional compounds: Inulin, Fructooligosaccharides (FOS), Zinc

\*Due to the big amount of published clinical studies with *L.rhamnosus* GG, only latest, robust reviews are listed

# Our probiotic blends - Pediatric health



DROPS

## AB-KOLICARE™

*B. longum* KABP™ 042  
*P. pentosaceus* KABP™ 041

### Indication

- Infant colic
- Microbiota development

Daily dose in final product: 1 billion CFU

### Scientific support

1. Santas JM, et al. *Pediococcus pentosaceus* CECT 8330 and *Bifidobacterium longum* CECT 7894 show a trend towards lowering infantile excessive crying syndrome in a pilot clinical trial. Int J Pharm Bio Sci. 6, 458-466 (2015).
2. Navarro-Tapia E, et al. Patient characteristics influencing infant colic amelioration under a probiotic treatment. Ann. Nutr. Metab. 74, 1-31 (2019).
3. Chen K, et al. The efficacy of 3 week's daily supplementation with a two-combined probiotic strains on infant colic. Manuscript submitted.
4. Tintore M, et al. Probiotic treatment with AB-KOLICARE causes changes in the microbiota which correlate with a reduction in crying time. Int. J. pharma Bio Sci. 8, 281-288 (2017).
5. Tintore M, et al. Gut microbiota dysbiosis and role of probiotics in infant colic. Arch. Clin. Microbiol. 08, 56 (2017).

Additional compounds: Vitamin D



SHOTS



STICKS



DROPS

## AB-DIGEST™

*B. longum* KABP™ 042  
*P. pentosaceus* KABP™ 041  
*L. rhamnosus* GG

### Indication

- Diarrhea, antibiotic co-treatment
- Microbiota restoration
- Immune support

Daily dose in final product: 6 billion CFU

### Scientific support\*

1. Szajewska H, et al. Meta-analysis: *Lactobacillus* GG for treating acute gastroenteritis in children--updated analysis of randomised controlled trials. Aliment Pharmacol Ther. 38, 467-76 (2013).
2. Szajewska H, et al. Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 42, 1149-57 (2015).
3. Tintore M, et al. Probiotic treatment with AB-KOLICARE causes changes in the microbiota which correlate with a reduction in crying time. Int. J. pharma Bio Sci. 8, 281-288 (2017).
4. Astó E, et al. Equivalence of a novel *Lactobacillus rhamnosus* isolate to the reference ATCC53103 strain. Poster presented at SEPyP congress (2018)

Additional compounds: Inulin, Fructooligosaccharides (FOS), Zinc

\*Due to the big amount of published clinical studies with *L.rhamnosus* GG, only latest, robust reviews are listed



# Our probiotic blends - Oral health



## AB-DENTALAC™

*L. plantarum* KABP™ 051  
*L. brevis* KABP™ 052  
*P. acidilactici* KABP™ 053

### Indication

- Protection after oral surgery
- Gingivitis, caries, halitosis, dental plaque
- Teeth whitening

Daily dose in final product: 1 billion CFU

### Scientific support

1. Montero E, et al. Clinical and microbiological effects of the adjunctive use of probiotics in the treatment of gingivitis: A randomized controlled clinical trial. *J. Clin. Periodontol.* 44, 708–716 (2017).
2. Ferrés-Amat E, et al. Probiotics diminish the post-operative pain following mandibular third molar extraction: A randomised double-blind controlled trial (pilot study). *Benef. Microbes* 11, 631–639 (2020).
3. Calabuig RP, et al. Oral probiotic reduces pain after third molar extraction procedure. Poster presented at SEPyP congress (2019).
3. Bosch M, et al. Isolation and characterization of probiotic strains for improving oral health. *Arch Oral Biol.* 57, 539-349 (2012).

Additional compounds: Vitamin D



## AB-IMPLALAC™

*P. acidilactici* CECT 8904  
*P. pentosaceus* CECT 8905  
*P. acidilactici* CECT 8906

### Indication

- Peri-implantitis prevention
- Oral microbiota balance

Daily dose in final product: 1 billion CFU

### Scientific support

1. Clinical trial on-going: evaluation of the improvement of peri-implantitis state in implants treated with probiotics.

Additional compounds: Vitamin D

# Our probiotic blends - Cardiometabolic health



## AB-LIFE™

- L. plantarum* KABP™ 011
- L. plantarum* KABP™ 012
- L. plantarum* KABP™ 013

### Indication

- High cholesterol
- High triglycerides

Daily dose in final product: 1.2 billion CFU

### Scientific support

1. Fuentes MC, et al. A randomized clinical trial evaluating a proprietary mixture of *Lactobacillus plantarum* strains for lowering cholesterol. *Med. J. Nutrition Metab.* 9, 125–135 (2016).
2. Espadaler J, et al. Demographic and clinical characteristics influencing the effects of a cholesterol-lowering probiotic. *Ann. Nutr. Metab.* 74, 1–31 (2019).
3. Bosch M, et al. *Lactobacillus plantarum* CECT 7527, 7528 and 7529: Probiotic candidates to reduce cholesterol levels. *J. Sci. Food Agric.* 94, 803–809 (2014).
4. Kim DH, et al. Effect of mixture of *Lactobacillus plantarum* CECT 7527, 7528, and 7529 on obesity and lipid metabolism in rats fed a high-fat diet. *J. Korean Soc. Food Sci. Nutr.* 43, 1484–1490 (2014).
5. Mukerji P, et al. Safety evaluation of AB-LIFE®: Antibiotic resistance and 90-day repeated-dose study in rats. *Food Chem. Toxicol.* 92, 117–128 (2016).
6. Guerrero L, et al. Effect of AB-LIFE in combination with 10 mg of Monacolin K. Manuscript under preparation.

Additional compounds: Vitamin B1, Omega 3 (alpha linolenic acid)



## LipiGO®

*Saccharomyces cerevisiae* postbiotic (BGCC extract)

### Indication

- Prevents rebound effect
- Safe weight loss
- Overweight and type I obesity

Daily dose in final product: 3000 mg

### Scientific support

1. Santas J, et al. Effect of a polysaccharide-rich hydrolysate from *Saccharomyces cerevisiae* (LipiGO®) in body weight loss: randomised, double-blind, placebo-controlled clinical trial in overweight and obese adults. *J Sci Food Agric.* 97, 4250–7 (2017).
2. Gómez-Candela C, et al. Clinical trial to assess the benefits of regular consumption of LipiGO® on the weight rebound effect post-diet in obese and overweight individuals. Manuscript under preparation.
3. Santas J, et al. Polysaccharide-rich hydrolysate from *Saccharomyces cerevisiae* (LipiGO®) increases fatty acid and neutral sterol excretion in guinea pigs fed with hypercholesterolemic diets. *Eur J Lipid Sci Technol.* 119, 17001-04 (2017).

# Our probiotic blends - Brain health



CAPSULES



STICKS

## AB-MIND™

*L. plantarum* DR7

### Indication

- Stress and anxiety
- Emotional well-being
- Memory and cognition

Daily dose in final product: 1 billion CFU

Additional compounds: Magnesium

### Scientific support

1. Chong HX, et al. *Lactobacillus plantarum* DR7 alleviates stress and anxiety in adults: A randomised, double-blind, placebo-controlled study. *Benef. Microbes* 10, 355–373 (2019).
2. Liu G, et al. *Lactobacillus plantarum* DR7 modulated bowel movement and gut microbiota associated with dopamine and serotonin pathways in stressed adults. *Int. J. Mol. Sci.* 21, 4608 (2020).
3. Lew LC, et al. Effects of potential probiotic strains on the fecal microbiota and Metabolites of d-Galactose-Induced Aging Rats Fed with High-Fat Diet. *Probiotics Antimicrob. Proteins* 12, 545–562 (2020).

# Our probiotic blends - Immune health



## AB-DR7™

*L. plantarum* DR7

### Indication

- Upper respiratory tract infections (URTIs)
- Respiratory health

Daily dose in final product: 1 billion CFU

### Scientific support

1. Chong HX, et al. *Lactobacillus plantarum* DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: A randomized, double-blind, placebo-controlled study. *J. Dairy Sci.* 102, 4783–4797 (2019).
2. Altadill T, et al. Does *Lactoplantibacillus plantarum* DR7 reduce days of upper respiratory tract infections and fever? A post-hoc analysis of a randomized, placebo-controlled trial. *FASEB Journal* (2021).
3. Baud D, et al. Using probiotics to flatten the curve of coronavirus disease COVID-2019. *Pandemic. Front. Public Heal.* 8, (2020).
4. Lew LC, et al. Effects of potential probiotic strains on the fecal microbiota and metabolites of d-galactose-induced aging rats fed with high-fat diet. *Probiotics Antimicrob. Proteins.* 12, 545–562 (2020).

Additional compounds: Vitamin D, C, Zinc



## AB-IMMUNO™

*L. plantarum* KABP™ 031  
*L. plantarum* KABP™ 032

### Indication

- Immunity support
- Immunosenescence prevention

Daily dose in final product: 1 billion CFU

### Scientific support

1. Mañé J, et al. A mixture of *Lactobacillus plantarum* CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial. *Nutr. Hosp.* 26, 228-235 (2011).
2. Bosch M, et al. El consumo del probiótico *Lactobacillus plantarum* CECT 7315/7316 mejora el estado de salud general en personas de edad avanzada. *Nutr. Hosp.* 26, 642-645 (2011).
3. Bosch M, et al. *Lactobacillus plantarum* CECT 7315 and CECT 7316 stimulate immunoglobulin production after influenza vaccination in elderly. *Nutr. Hosp.* 27, 504–509 (2012).
4. Vilahur G, et al. *Lactobacillus plantarum* CECT 7315/7316 intake modulates the acute and chronic innate inflammatory response. *Eur. J. Nutr.* 54, 1161–1171 (2015).
5. Bosch M, et al. Probiotic properties of *Lactobacillus plantarum* CECT 7315 and CECT 7316 isolated from faeces of healthy children. *Lett. Appl. Microbiol.* 54, 240–246 (2012).

Additional compounds: Vitamin B<sub>9</sub>, B<sub>6</sub>, B<sub>12</sub>, C, A, Zinc, Selenium



# Our probiotic blends - Skin health



CAPSULES



STICKS

## AB-SAKEI 65®

*L. sakei* proBio 65

### Indication

- Atopic dermatitis
- Skin redness and discomfort

Daily dose in final product: 5 billion CFU

Additional compounds: Zinc

### Scientific support

1. Woo SI, et al. Effect of *Lactobacillus sakei* supplementation in children with atopic eczema-dermatitis syndrome. *Ann. Allergy, Asthma Immunol.* 104, 343–348 (2010).
2. Park SB, et al. Effect of emollients containing vegetable-derived lactobacillus in the treatment of atopic dermatitis symptoms: Split-body clinical trial. *Ann. Dermatol.* 26, 150–155 (2014).
3. Rather IA, et al. Oral administration of live and dead cells of *Lactobacillus sakei* proBio65 alleviated atopic dermatitis in children and adolescents: a randomized, double-blind, and placebo-controlled Study. *Probiotics Antimicrob. Proteins* (2020).
4. Lim J, et al. Immune-modulating characteristics of *Lactobacillus sakei* proBio65 isolated from Kimchi. *Korean J. Microbiol. Biotechnol.* 39, 313-316 (2011).
5. Kim JY, et al. Atopic dermatitis-mitigating effects of new *Lactobacillus* strain, *Lactobacillus sakei* probio 65 isolated from Kimchi. *J. Appl. Microbiol.* 115, 517–526 (2013).

# Our probiotic blends - Women's health



CAPSULES

## AB-CYSCARE™

*L. plantarum* KABP™ 062  
*L. plantarum* KABP™ 063

### Indication


- Urinary tract infections (UTIs)
- Urogenital microbiota balance

Daily dose in final product: 1 billion CFU

### Scientific support\*

1. Simón E, et al. Screening of *Lactobacilli* strains of human origin candidates for the prevention of urinary tract infections. *Ann. Nutr. Metab.* 74, 1–31 (2019).
2. Padayatty SJ, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. *J Am Coll Nutr.* 22, 18-35 (2003)
3. Ochoa-Brust GJ, et al. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy. *Acta. Obstet. Gynecol. Scand.* 86, 783-7 (2007).
4. Wang CH, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med.* 172, 988-96 (2012).
5. Salo J, et al. Cranberry juice for the prevention of recurrences of urinary tract infections in children: a randomized controlled trial. *Clin Infect Dis.* 54, 340-6 (2012).

Additional compounds: Cranberry extract, Vitamin C



VAGINAL TABLETS



CAPSULES

## INNERIM™

*L. plantarum* KABP™ 061

### Indication

- Vaginal candidiasis
- Vaginal microbiota balance

Daily dose in final product: 0.1 billion CFU

### Scientific support

1. Palacios S, et al. Is it possible to prevent recurrent vulvovaginitis? Role of *Lactobacillus plantarum* I1001 (CECT7504). *Eur J Clin Microbiol. Infect. Dis.* 35, 1701-8 (2016).
2. Clinical trial on-going: Interventional study to evaluate the effect of the oral administration of *L. plantarum* on vaginal microbiota (NCT04461782).

\*Clinical trials and meta-analyses of AB-CYSCARE added compounds (cranberry extract, vitamin C) are also listed.

# Our probiotic blends - Eye health



EYE DROPS

## AB-PROTEARS®

*L. sakei proBio 65*

### Indication

- Ocular irritation
- Allergies and inflammation of the eye surface

Daily dose in final product: 1 billion CFU

### Scientific support

1. Clinical trial on-going
2. *In vivo* testing for skin sensitization and ocular irritation


## Quality standards



patented products



clinically-proven  
and safe



organic strains,  
natural origin



allergen-free



Qualified Presumption  
of Safety status (EFSA)



not modified  
genetically



Generally Recognised as Safe  
(FDA) and/or Natural Product  
Number (Health Canada)



## As a leading B2B company with global presence:

### **We support our partners throughout product lifespan**

R&D, market access and marketing specialists. Complete, personalised support every step of the way

### **We adapt to our partners' aspirations and needs**

Co-development of probiotic solutions following market trends

